Sanofi Tests mRNA Vaccine for Acne in Two Trials of 1,028 Adults
(MENAFN) French drugmaker Sanofi is enrolling adults aged 18 to 45 in two clinical studies of an experimental mRNA vaccine as a possible acne treatment, according to its clinical trials website.
Both studies are listed as recruiting. One targets mild facial acne, the other moderate to severe cases. Each combines phase 1 and phase 2 research to assess the candidate’s safety, the immune response it triggers and whether it improves acne.
The larger trial, registered as NCT06316297, aims to enroll 800 people with moderate to severe acne. Researchers will test up to four dose levels, and participants will receive either two or three intramuscular injections depending on their group. Sanofi said the results would help researchers choose a dose and vaccination schedule for any later-stage efficacy trials.
The second trial, NCT07013747, aims to enroll 228 people with mild acne. It will test two injections at a single dose level. An initial group will undergo stepwise safety assessments before the main group begins.
Both protocols include optional long-term follow-up. Some participants would be monitored for a further 30 months after their final scheduled core-study visit to assess longer-term effects.
The vaccine remains investigational. The studies are designed to determine whether it can safely and effectively treat people who already have acne, a chronic inflammatory skin condition especially common among adolescents and young adults. Treatment typically aims to control lesions, reduce flare-ups and prevent permanent scarring.
Both studies are listed as recruiting. One targets mild facial acne, the other moderate to severe cases. Each combines phase 1 and phase 2 research to assess the candidate’s safety, the immune response it triggers and whether it improves acne.
The larger trial, registered as NCT06316297, aims to enroll 800 people with moderate to severe acne. Researchers will test up to four dose levels, and participants will receive either two or three intramuscular injections depending on their group. Sanofi said the results would help researchers choose a dose and vaccination schedule for any later-stage efficacy trials.
The second trial, NCT07013747, aims to enroll 228 people with mild acne. It will test two injections at a single dose level. An initial group will undergo stepwise safety assessments before the main group begins.
Both protocols include optional long-term follow-up. Some participants would be monitored for a further 30 months after their final scheduled core-study visit to assess longer-term effects.
The vaccine remains investigational. The studies are designed to determine whether it can safely and effectively treat people who already have acne, a chronic inflammatory skin condition especially common among adolescents and young adults. Treatment typically aims to control lesions, reduce flare-ups and prevent permanent scarring.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment